- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02871596
Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds
February 21, 2017 updated by: Pharmanex
Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds - a Randomized, Placebo-controlled, Double-blind, Cross-over Study
The purpose of the study is to determine the effects of both an anthocyanin-rich polyphenol blend and an anthocyanin-rich polyphenol blend combined with a prebiotic blend on fecal microbiota metabolism (assessed by gas chromatograph - mass spectrometry (GC-MS) headspace analysis) and fecal microbiota composition (assessed by next generation sequencing).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Utah
-
Logan, Utah, United States, 84322
- Utah State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female of any race or ethnicity between 18 to 70 years of age, inclusive;
- Body mass index (BMI) between 20 - 32 inclusive;
- Non-smoking status;
- Willing to consume assigned dietary supplements for a total of 6 weeks;
- Have access to email and a digital camera or camera phone.
Exclusion Criteria:
- Age <18 or >70 years;
- BMI <20 or >32;
- Uncontrolled hypertension defined as diastolic blood pressure ≥95 mm Hg or systolic blood pressure ≥160 mm Hg;
- Self-reported presence of atherosclerotic disease and/or cardiopulmonary disease;
- Renal, hepatic, endocrine, gastrointestinal or other systemic disease;
- For women, pregnancy, breast feeding or postpartum less than 6 months;
- Current participation in another research study;
- Allergy to the components in the dietary supplement (inulin, fructooligosaccharide, blueberries, black currant, rice);
- History of drug or alcohol abuse;
- Use of antibiotics within the last 6 months;
- Use of prebiotics or flavonoid-containing dietary supplements within the last 30 days;
- Multiple food allergies or significant food preferences or restrictions that would interfere with diet adherence;
- Chronic use of over-the-counter medication which would interfere with study endpoints including NSAIDS, laxatives and antacids;
- Participating in or planning to begin a weight loss diet during the study period;
- Lifestyle or schedule incompatible with the study protocol;
- Other medical, psychiatric, or behavioral conditions that in the view of the principal investigator may present a safety hazard to the participant or interfere with study participation or the ability to follow the intervention protocol;
- Use of tobacco products.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Placebo,Flavonoids,Flavonoids+Prebiotics
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
|
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
|
Experimental: Placebo,Flavonoids+Prebiotics,Flavonoids
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
|
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
|
Experimental: Flavonoids,Placebo,Flavonoids+Prebiotics
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
|
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
|
Experimental: Flavonoids,Flavonoids+Prebiotics,Placebo
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
|
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
|
Experimental: Flavonoids+Prebiotics,Placebo,Flavonoids
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
|
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
|
Experimental: Flavonoids+Prebiotics,Flavonoids,Placebo
Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
|
A combination of maltodextrins and red and blue food colors.
A combination of blueberry extract, black current extract, and black rice extract.
A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in fecal volatile methyl sulfides at day 21, day 63, day 105
Time Frame: baseline, day 21, day 63, day 105
|
assessed by gas chromatograph - mass spectrometry (GC-MS) headspace analysis
|
baseline, day 21, day 63, day 105
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in all fecal VOCs at day 21, day 63, day 105
Time Frame: baseline, day 21, day 63, day 105
|
baseline, day 21, day 63, day 105
|
Change from baseline fecal short chain fatty acids at day 21, day 63, day 105
Time Frame: baseline, day 21, day 63, day 105
|
baseline, day 21, day 63, day 105
|
Change from baseline fecal microbiota composition at day 21, day 63, day 105
Time Frame: baseline, day 21, day 63, day 105
|
baseline, day 21, day 63, day 105
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2016
Primary Completion (Actual)
February 1, 2017
Study Completion (Actual)
February 1, 2017
Study Registration Dates
First Submitted
August 15, 2016
First Submitted That Met QC Criteria
August 15, 2016
First Posted (Estimate)
August 18, 2016
Study Record Updates
Last Update Posted (Actual)
February 23, 2017
Last Update Submitted That Met QC Criteria
February 21, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- 16-PHX-0003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States